Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming Group N.V (PHAR) Inventory: 2019-2025

Historic Inventory for Pharming Group N.V (PHAR) over the last 5 years, with Sep 2025 value amounting to $67.1 million.

  • Pharming Group N.V's Inventory rose 7.89% to $67.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $67.1 million, marking a year-over-year increase of 7.89%. This contributed to the annual value of $55.7 million for FY2024, which is 1.89% down from last year.
  • Pharming Group N.V's Inventory amounted to $67.1 million in Q3 2025, which was up 5.37% from $63.7 million recorded in Q2 2025.
  • Pharming Group N.V's Inventory's 5-year high stood at $67.1 million during Q3 2025, with a 5-year trough of -$10.7 million in Q2 2023.
  • For the 3-year period, Pharming Group N.V's Inventory averaged around $51.9 million, with its median value being $56.8 million (2023).
  • Per our database at Business Quant, Pharming Group N.V's Inventory slumped by 278.95% in 2021 and then soared by 159,390.84% in 2023.
  • Quarterly analysis of 5 years shows Pharming Group N.V's Inventory stood at -$2.4 million in 2021, then grew by 19.49% to -$2.0 million in 2022, then skyrocketed by 2,981.79% to $56.8 million in 2023, then fell by 1.89% to $55.7 million in 2024, then grew by 7.89% to $67.1 million in 2025.
  • Its Inventory was $67.1 million in Q3 2025, compared to $63.7 million in Q2 2025 and $59.3 million in Q1 2025.